Lobbying giant PhRMA reported revenues of more than $600 million in 2021, a new record for the group.
by Donald Shaw, Sludge
In 2021, as Americans consumed record amounts of vaccines and other pharmaceuticals, the drug industry’s chief lobbying group surpassed $609 million in revenues, according to tax documents obtained by Sludge.
The Pharmaceutical Research and Manufacturers of America’s (PhRMA) $609 million in revenue in 2021 is a new record for the group, which has been rapidly growing in recent years. In its 2020 filing, it reported revenue of $573 million. Its revenue has more than doubled in the past five years.

In 2021, PhRMA also spent more money than ever on lobbying the federal government, reporting to Congress expenditures of more than $29.3 million. Combined with political expenditures, PhRMA’s 2021 tax filing says it spent more than $205 million on non-deductible lobbying. This sum includes amounts spent on influencing legislation, intervening in political campaigns, communicating with government officials, or attempting to influence the general public. PhRMA spent more on federal lobbying in 2021 than just two other organizations, according to OpenSecrets.
Americans’ use of medicines has steadily grown over the years. According to research by IQVIA Institute, the use of medicines in the U.S. grew by 9.6% over the last five years. Overall, spending on U.S. medicines rose by 12% in 2021, primarily due to COVID-19 vaccines and therapies, according to IQVIA.
Recent Posts
How to Organize Safely in the Age of Surveillance
February 22, 2026
Take Action Now From threat modeling to encrypted collaboration apps, we’ve collected experts’ tips and tools for safely and effectively building a…
‘The Siege Must Be Broken’: Countries Called to Ship Fuel to Cuba After Trump Tariffs Struck Down
February 21, 2026
Take Action Now The US Supreme Court’s ruling “implies that Trump’s recent order imposing tariffs on countries selling oil to Cuba exceeds the…
Elite Depravity in Imperial Decline, A Zero Hour Conversation With Richard Wolff
February 20, 2026
Take Action Now “The system self-selects for psychopathy… the most sociopathically obsessive competitor and accumulator of personal power and…
Economics of Health For All: The Plan to Put Health at the Heart of the Global Economy
February 20, 2026
Take Action Now At the World Health Assembly in May, member states may endorse an unprecedented strategy declaring that health is not a cost – but…




